Vanguard Fiduciary Trust
TPST icon

Vanguard Fiduciary Trust’s Tempest Therapeutics TPST Stock Holding History

Vanguard Fiduciary Trust’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76.5K Hold
68,908
– – ﹤0.01% 3785
2026
Q1 		$113K Buy
+68,908
New +$166K ﹤0.01% 3687

Other funds holding TPST

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Vanguard Fiduciary Trust's TPST Position: Q2 2026 in Review

Vanguard Fiduciary Trust held its Tempest Therapeutics (TPST) position steady in Q2 2026 at 68,908 shares worth $76.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3785.

Vanguard Fiduciary Trust first reported a position in TPST in Q1 2026 and has held it in 2 quarters since. The position peaked at $113K in Q1 2026. 21 funds tracked by Wall St. Rank hold TPST as of Q2 2026.

  • Vanguard Fiduciary Trust held 68,908 shares of Tempest Therapeutics worth $76.5K as of Q2 2026.
  • Vanguard Fiduciary Trust left its Tempest Therapeutics share count unchanged in Q2 2026.
  • Tempest Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3785 holding.
  • Vanguard Fiduciary Trust first reported a position in Tempest Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Tempest Therapeutics position peaked at $113K in Q1 2026.
  • 21 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.